Skip to main content
Premium Trial:

Request an Annual Quote

Whatman Plans to Lay Off 160, Provides Details on Schleicher & Schuell Acquisition

NEW YORK, Jan. 3 (GenomeWeb News) - Whatman announced last week that a review of its business operations following the Dec. 1 acquisition of Schleicher & Schuell has been completed, and that the company has decided to cut approximately 160 jobs.

 

This reduction will reduce Whatman's headcount to about 1000, and result in a one-time charge of £11.4 million, the company said. Whatman announced in early November that it would be acquiring Schleicher & Schuell for €50.2 million.

 

Whatman also said that its US manufacturing operations will be focused in Stanford, Maine. Its US sales and administrative operations, as well as global business development activities, will be centered in Florham Park, NJ.

 

Additionally, former Schleicher & Schuell head office functions will be intergrated into Whatman and "streamlined," while the sales and business development activities of the two companies will be combined and "optimized."

 

Whatman said that it is working to narrow the product offerings of the companies from 21,000 to 7,000, an effort that will cost about £800,000. An additional £2.4 million charge unrelated to the Schleicher & Schuell acquisition will also be recorded in 2004.

 

In total, Whatman expects to record a charge of £14.6 million in 2004, of which the pre-tax cash cost is £13.8 million.

 

The company said its sales for the year are "disappointing," coming in about three percent lower than expected, but that earnings before exceptional charges remain in-line with expectations.

 

Preliminary results for the full-year 2004 will be released in April, Whatman said.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.